Opinion
Video
Neonatal Fc Receptors in Treatment of Generalized Myasthenia Gravis
Author(s):
Key Takeaways
- FcRn-targeting agents for gMG vary in their mechanisms, primarily by inhibiting FcRn to lower pathogenic IgG levels or modulating immune responses.
- Both approved and investigational FcRn-targeting drugs possess distinct pharmacological profiles, impacting their therapeutic applications.
Panelists discuss how various approved and investigational FcRn-targeting agents differ in their mechanisms of action for treating generalized myasthenia gravis (gMG).
Video content above is prompted by the following:
- A number of agents targeting the neonatal Fc receptor (FcRn) have recently been approved or are under investigation to treat gMG. What are the differences regarding mechanism of action among the following approved or investigational FcRn-targeting agents?
Related Videos
Related Content
